As of Feb 16
| +0.0201 / +9.11%|
The 1 analysts offering 12-month price forecasts for Mateon Therapeutics Inc have a median target of 1.00, with a high estimate of 1.00 and a low estimate of 1.00. The median estimate represents a +316.58% increase from the last price of 0.24.
The current consensus among 1 polled investment analysts is to Buy stock in Mateon Therapeutics Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.